Amanote Research
Register
Sign In
Correction: ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-19-0632
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
July 1, 2019
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Author Correction: PAK Signalling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas
Nature
Multidisciplinary
A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-mutant Melanoma
Cancer Research
Cancer Research
Oncology
809 Pou4f1 Promotes Braf Inhibitor Resistance by Reactivating Mapk Signaling Pathway in Melanoma
Journal of Investigative Dermatology
Biochemistry
Dermatology
Cell Biology
Molecular Biology
Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma
PLoS ONE
Multidisciplinary
mTORC1/autophagy-regulated MerTK in Mutant BRAFV600 Melanoma With Acquired Resistance to BRAF Inhibition
Oncotarget
Oncology
Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
Frontiers in Oncology
Cancer Research
Oncology
Cessation of Targeted Therapy After a Complete Response in BRAF-mutant Advanced Melanoma: A Case Series
British Journal of Cancer
Cancer Research
Oncology
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer
Cancer Research
Cancer Research
Oncology
Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
Molecular Cancer Therapeutics
Cancer Research
Oncology